Gravar-mail: PHASE I TRIAL OF A BIVALENT GANGLIOSIDES VACCINE IN COMBINATION WITH β-GLUCAN: FOR HIGH-RISK NEUROBLASTOMA IN SECOND OR LATER REMISSION